home / stock / pdsb / pdsb news

PDSB News and Press, PDS Biotechnology Corporation From 05/20/21

Stock Information
Company Name: PDS Biotechnology Corporation
Stock Symbol: PDSB
Market: NASDAQ
Website: pdsbiotech.com
Menu
PDSB PDSB Quote PDSB Short PDSB News PDSB Articles PDSB Message Board
Get PDSB Alerts

News, Short Squeeze, Breakout and More Instantly...
PDSB - PDS Biotech Announces Release of Abstract for PDS0101 in NCI-Led Phase 2 Clinical Study for Oral Presentation at 2021 ASCO Meeting

FLORHAM PARK, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune ® T-cell activating technology, today announced publicatio...
PDSB - PDS Biotechnology Appoints Immuno-Oncology Experts Dr. Olivera Finn and Dr. Mark Frohlich to Scientific Advisory Board

FLORHAM PARK, N.J., May 18, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating techno...

PDSB - PDS Biotech Receives $4.5M After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program

FLORHAM PARK, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology,...

PDSB - PDS Biotechnology Corp (PDSB) CEO Frank Bedu-Addo on Q1 2021 Results - Earnings Call Transcript

PDS Biotechnology Corp (PDSB) Q1 2021 Earnings Conference Call May 13, 2021, 08:00 ET Company Participants Deanne Randolph - VP, Commericial Development & Head, IR Frank Bedu-Addo - President, CEO & Director Lauren Wood - Chief Medical Officer Seth Van Voorhees - CFO, Principal Financ...
PDSB - PDS Biotechnology EPS beats by $0.05

PDS Biotechnology (PDSB): Q1 GAAP EPS of -$0.14 beats by $0.05.Cash balance as of March 31, 2021 was approximately $25.0 million.Shares +2.2%.Press Release For further details see: PDS Biotechnology EPS beats by $0.05

PDSB - PDS Biotech Provides Business Update and Reports First Quarter 2021 Financial Results

FLORHAM PARK, N.J., May 13, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating techno...

PDSB - PDS Biotech Announces Oral Presentation of PDS0101 Data by the National Cancer Institute at 2021 American Society of Clinical Oncology Annual Meeting

FLORHAM PARK, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating tec...
PDSB - PDS Biotechnology Announces Conference Call and Webcast for First Quarter Financial Results

FLORHAM PARK, N.J., April 26, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating ...

PDSB - PDS Biotech Announces Participation in Noble Capital Markets Virtual Road Show Series

Florham Park, NJ, April 19, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology,...

PDSB - PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q4 2020 Results - Earnings Call Transcript

PDS Biotechnology Corporation (PDSB) Q4 2020 Earnings Conference Call March 18, 2021 08:00 A.M. ET Company Participants Deanne Randolph - IR Frank Bedu-Addo - CEO Lauren V. Wood - CMO Seth L. Van Voorhees - CFO Conference Call Participants Joseph Pantginis - H.C. Wainwright & Company Trev...
Previous 10 Next 10